Nesrin Besbas

TL;DR: The features of the disease in the Turkish population are described and it is shown that amyloidosis is still a substantial problem, even among the 18 patients with a disease onset after age 40 years.

TL;DR: The need for prospective studies to establish evidence-based criteria for the continuation or cessation of anticomplement therapy in patients with and without identified complement mutations is discussed.

TL;DR: This guideline for the investigation and initial treatment of atypical hemolytic uremic syndrome is intended to offer an approach based on opinion, as evidence is lacking, and builds on the current ability to identify the etiology of specific diagnostic sub-groups of HUS.

TL;DR: A high frequency of carriers in the healthy Turkish population (20%) was found and the distribution of the five most common MEFV mutations among healthy individuals was significantly different from that found in patients.

TL;DR: A classification that accommodates both a current understanding of causation and clinical association in cases for whom cause of disease is unclear is proposed and is expected to increase the proportion of cases in whom a level 1 etiological diagnosis is confirmed.